BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
The information in this Current Report is being furnished to Item
2.02 of Form 8-K and, according to general instruction B.2.
thereunder, the information in this Current Report shall not be
deemed filed for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of
that Section. The information in this Current Report shall not be
incorporated by reference into any registration statement to the
Securities Act of 1933, as amended.
On March 15, 2017, Bio-Path Holdings, Inc. (the Company) issued a
press release announcing financial results for the year ended
December 31, 2016. Additional information is included in the
Companys press release. A copy of such press release is attached
hereto as Exhibit 99.1. The foregoing description of such press
release is qualified in its entirety by reference to the attached
Exhibit 99.1.
Item 7.01 Regulation FD Disclosure.
On March 14, 2017, the Company issued a press release titled,
Bio-Path Holdings to Present at the Oppenheimer 27th Annual
Healthcare Conference. A copy of such press release is attached
hereto as Exhibit 99.2.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits.
| Exhibit Number | Description |
| 99.1 | Press Release dated March 15, 2017 |
| 99.2 | Press Release dated March 14, 2017 |
About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Recent Trading Information
BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) closed its last trading session up +0.004 at 0.940 with 99,456 shares trading hands.